ID
24539
Description
Study part: International RLS Rating Scale. A 52-Week, Open-Label Study to Assess the Long-Term Safety of Ropinirole Extended Release (XR) in Patients with Restless Legs Syndrome (RLS). Patient Level Data: Study Listed on ClinicalStudyDataRequest.com. Clinicaltrials.gov Identifier: NCT00355641. Phase: phase 3. Study Recruitment Status: Completed. Generic Name: ropinirole. Trade Name Modutab, ZIPEREVE, ZEPREVE, REPREVE, ADARTREL, REQUIP, Zygara; Zygara, ZIPEREVE, ZEPREVE, Requip Depot, REQUIP, REPREVE, Modutab, ADARTREL. Study Indication : Restless Legs Syndrome. Study ID: 101468/206. Clinical Study ID: 101468/206.
Keywords
Versions (1)
- 8/5/17 8/5/17 -
Copyright Holder
GlaxoSmithKline
Uploaded on
August 5, 2017
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
International RLS Rating Scale (IRLSRS) Ropinirole Restless Legs Syndrom NCT00355641
International RLS Rating Scale
- StudyEvent: ODM
Similar models
International RLS Rating Scale
- StudyEvent: ODM
C0035258 (UMLS CUI-2)
C0035258 (UMLS CUI [1,2])
No comments